Information Provided By: 
Fly News Breaks for May 12, 2017
SRPT
May 12, 2017 | 12:46 EDT
After the FDA posted briefing documents ahead of a joint meeting on May 18 to vote on a parent's request for the inclusion of alternative venous access device in Sarepta's Phase III ESSENCE study of SRP-4045 and SRP-4053, Piper Jaffray analyst Edward Tenthoff said the decision should not impact the planned interim efficacy analysis after 48-week data are available, but a "Yes" vote would be beneficial for DMD boys and potentially lower discontinuation rates. He maintains his $43 price target and Overweight rating on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
